Skip to main content
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. — Investor Relations & Filings

Ticker · CADL ISIN · US1374041093 US Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2023-03-30 Regulatory Filings
Country US United States of America
Listing US CADL

About Candel Therapeutics, Inc.

https://www.candeltx.com/

Candel Therapeutics, Inc. is a company developing viral immunotherapies designed to activate a patient's immune system to fight cancer. Its approach utilizes two main platforms based on engineered adenovirus and Herpes Simplex Virus (HSV). These investigational, off-the-shelf therapies are administered directly into tumors to induce immunogenic cell death. This process is intended to stimulate a personalized, systemic, and durable anti-tumor response specific to the individual's cancer. The company aims to create treatments that are both efficacious and well-tolerated for patients across various disease stages.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option and employee stock purchase plans. It includes details about the plans, exhibits, consents, and signatures of officers and directors. This type of filing is related to registering securities for employee compensation plans and is not a financial report, earnings release, or management discussion. It is a regulatory filing specific to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice but a full registration statement.
2023-03-30 English
10-K
Annual Report FY 2022
2023-03-30 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 30, 2023, reporting the results of operations and financial condition for the quarter and year ended December 31, 2022. It includes a press release as Exhibit 99.1 announcing financial results. The text states that the full financial results are in the press release attached, and the document itself is a current report filing rather than a full earnings release or annual report. The document length is 3590 characters, which is relatively short and mainly serves as an announcement of financial results rather than containing detailed financial statements or analysis. According to the rules, such filings that announce financial results but do not contain the full detailed financial data themselves are classified as Earnings Release (ER). The presence of a press release announcing quarterly and annual financial results aligns with the ER category.
2023-03-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a change in the primary endpoint of a clinical trial and the impact on the timing of top-line results. It does not contain financial statements or detailed financial analysis. The document is relatively short (4127 characters) and serves as a disclosure of a material event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-02-22 English
FORM 4/A SUBMISSION
Director's Dealing
2023-02-18 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.